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Min Kang, Wen-Qi Liu, Yu-Tao Qin, Zhu-Xin Wei, Ren-Sheng Wang* cells are as follows. Firstly, hyperthermia has cytotoxic effects on tumor cells. The thermo sensitivity of tumor cells is higher than normal cells. Tumor cells would be killed after treatment at 42°C for 2 h. Due to their high thermo sensitivity, the temperature of tumor cells is 3°C-7°C higher than that of surrounding normal tissues when heating. Therefore, appropriate hyperthermia will directly kill tumor cells without injuring surrounding normal tissues. Secondly, radiation-insensitive tumor cells are mainly S phase cells and hypoxic cells, which are highly sensitive to hyperthermia. Thirdly, hyperthermia can inhibit the damage repair of tumor cells after radiotherapy (Zastrow et al., 2010; Ghahremani et al., 2011; Colombo and Moschini, 2013) . Fourthly, because of the sufficient blood supply in tumor surrounding tissues, the cytotoxicity of hyperthermia on surrounding tissues is much less severe than that on tumor center. The hyperthermia treatment failure is mainly due to the peripheral tumor recurrence while radiotherapy failure is mainly due to local recurrence in the tumor center. Therefore, combination of hyperthermia and radiotherapy can have a synergistic sensitizing effect (Perez and Brady, 1987; Nikfarjam et al., 2005) . Fifthly, hyperthermia can upregulate expression of pro-apoptotic genes while downregulate expression of apoptosis suppressor genes . Sixthly, hyperthermia enhances cytotoxicity of some chemotherapy drugs, such as cisplatin. In vitro experiments (Zheng et al., 2006) showed that the anti-cancer effect of chemotherapy drugs can be enhanced 10 to 100 times after heating at 42°C for 2 h. Combination of heating and chemotherapy drug can increase the drug concentration within the tumor and increase its anticancer effect. And the toxicity of chemotherapy drugs on unheated normal tissues can be reduced, which will help prevent or delay the drug resistance. Therefore, it is shown by a number of clinical trials that the efficacy of combined treatment including hyperthermia, radiotherapy and chemotherapy were better than the efficacy of each therapy alone (Song et al., 2006; Chen et al., 2009) .
Currently, the specific details of hyperthermia treatment such as timing, treatment times and temperature are still controversial. In this study, the long-term effect of hyperthermia in combination with radiotherapy and chemotherapy on NPC patients with cervical lymph node metastasis was investigated. A total of 154 cases of NPC patients at stage N2 ~ N3 were enrolled in this study. The complete response rate, the disease-free-survival rate and the survival rate were analyzed. The number, temperature and timing of hyperthermia were compared.
Materials and Methods
Patient Selection
Patients who fulfilled all of the following criteria were enrolled in this study: (1) NPC confirmed by biopsy and histology; (2) no evidence of distant metastasis; (3) no previous treatment for NPC; (4) T1-4N2-3M0 disease according to the staging system of the 2002 American Joint Committee on Cancer (AJCC) / International Union Against Cancer (UICC) (Fleming et al., 1997) ; (5) adequate liver function; (6) adequate renal function; (7) adequate bone marrow function; and (8) Karnofsky performance status (KPS) ≥80. The exclusion criteria were as follows: (1) presence of distant metastases; (2) pregnancy or lactation; (3) previous malignancy or other concomitant malignant disease; and (4) without previous radiotherapy, chemotherapy or immunotherapy.
Pretreatment Evaluation
Pretreatment evaluation included a complete history and physical examination with nasopharyngoscopy, chest radiography, ultrasonography of the abdominal region, and hematologic and biochemical profiles. Additional investigations were performed if indicated. Magnetic resonance imaging (MRI) and Contrast-enhanced computed tomography (CT) of the nasopharyngeal region and neck were performed to determine stage. Prior written and informed consent was obtained from every patient and the study was approved by the ethics review board of Guangxi Medical University.
Treatment method
(1) Control group: Control group received radiotherapy combined with chemotherapy. Radiotherapy was performed by weekly exposure of 2Gy per day for 5 days. The primary foci firstly received X ray of 6 MV on face and neck with a dose of DT36Gy. Afterwards, fields before ear of both sides received radiation of DT34 ~ 40 Gy. The total radiation for nasopharynx was DT70 ~ 78Gy, 35 to 39 times and 47 to 51 d in total. After the 6 MV perpendicular X ray radiation dose on cervical lymph node metastasis site reached 50Gy, 9 to 12 MeV electron beam radiation was used as supplement with total vertical radiation amount of DT68 ~ 72 Gy for 34 ~ 36 times in total of 46 ~ 50 d on the neck and with prophylactic dose of DT50 ~ 54 Gy.
Concurrent chemotherapy was performed during radiotherapy, which consisted of cisplatin alone (80 mg/ (2) Hyperthermia group: Radiotherapy and chemotherapy in hyperthermia group was the same as the control group. Pingliang 778WR-L-4 microwave hyperthermia machine (Sunostick Medical Technology Co., Ltd, London, UK), with frequency of 915 MHz and external heating diameter of 80 mm or 150 mm, was used for hyperthermia. Different types of radiators were used according to different tumor sizes and the radiator was 2 to 4 cm above the surface. The hyperthermia site was cooled with water bags. SYI thermal system (Sunostick Medical Technology Co.,Ltd, London, UK) was used to measure temperature of tumor center and surrounding area. And the surface temperature was maintained at 41.5°C to 42°C. Temperature measurement was performed 1 h before and after radiotherapy, and heating time was recorded every time. The duration of effective heating was 45 min, 2 times per week and 3 to 14 times in total.
For comparison of effect of hyperthermia pattern on regression, 36 patients received hyperthermia before radiotherapy and 40 patients received hyperthermia after radiotherapy. For comparison of effect of heating temperature on regression, 70 patients with well temperature curve were further divided into patients with T90 < 43°C treatment (28 cases) and patients with T90 ≥ 43°C treatment (42 cases). And to compare effect of heating time on regression, 15 cases received heating of < 4 times, 38 cases were treated with heating of 4-10 times and 23 cases received heating of > 10 times.
Patient evaluation and follow-up
All patients were evaluated at least once a week during the radiotherapy. The first assessment of tumor response was performed 1 month after the completion of radiotherapy by physical examination and flexible nasopharyngoscopy. This was followed by contrastenhanced CT of the head and neck 3 months after radiotherapy. Then patients were followed up every 3 months from 3 months through 3 years, and every 1 year thereafter for 5 years. During every follow-up visit, disease status and treatment toxicity were assessed. Complete physical and fiberoptic nasopharyngoscopy or indirect nasopharyngeal speculum examinations were performed.
The assessments included blood tests, biochemistry profiles, chest radiography, abdominal ultrasonography, and CT of the nasopharynx and cervical region. Further investigations were arranged as indicated. Management of residual disease and tumor relapse, if detected, was determined on a case-by-case basis. Nasopharynx MRI should be performed every six months. Local or cervical lymph node recurrence was examined by pathologic diagnosis. Suspicious metastasis was analyzed by thoracic and abdominal CT and bone scintigraphy. Acute and late adverse reaction was evaluated by standards of USA Radiation Therapy Oncology Group or European Organization for Research and Treatment of Cancer . Efficacy evaluation was in accordance with WHO Response Evaluation Criteria in Solid Tumors and classified as complete response (CR), partial response (PR), incomplete response/stable disease (SD) and progressive disease (PD). Neck mass was assessed by CT results. Regression of cervical lymph nodes was assessed 3 months after treatment. Complete regression was recorded as CR, and tumor size regression ≥ 50% was PR.
Statistical analysis SPSS 17.0 software was used for statistical analysis. The Kaplan-Meier (Kaplan and Meier, 1958) method was used to compare the overall survival rate. Pearson ChiSquare test was used for the analysis of distant metastasis rate, disease-free survival rate (DFS) and local control rate. P < 0.05 was considered statistically significant.
Results
Regression rate of cervical lymph nodes in hyperthermia group is higher at 3 months after treatment
At 3 months after treatment, regression rate of cervical lymph nodes was evaluated. As shown in Table 2 , the CR rate in hyperthermia treatment group and control group was 81.6% and 62.8%, respectively. And the difference between these two groups was significantly different (P < 0.05). Thus hyperthermia group had higher regression rate of cervical lymph nodes.
The 3-year and 5-year survival rates in hyperthermia group are higher
The follow-up was ended in May 2012, or 5 years after treatment or patient death, with a median followup time of 58 months. The follow-up was performed by telephone or letters and with successful rate of 96.1% (148/154). The 1-year, 3-year and 5-year survival rates were calculated. The results were shown in Table 2 . The 1-year survival rate in hyperthermia group and control group was 97.4% and 93.6%, respectively. The 3-year survival rate in hyperthermia group and control group was 85.5% and 61.5%, and the 5-year survival rate was 68.4% and 50.0%, respectively. Statistically, there were significant differences in the 3-year and 5-year survival rate (P < 0.05), but not the 1-year survival rate (P > 0.05), between the hyperthermia group and control group. Therefore, hyperthermia group had higher 3-year and 5-year survival rates.
Hyperthermia group has higher local control rate and DFS rate
At 5 years after treatment, the local control rate, the distant metastasis rate and DFS rate were analyzed. As shown in Table 2 , there was significant difference in local control rate (96.1% vs. 76.9%) and 5-year DFS rate (51.3% vs. 20.5%) between hyperthermia group and control group (P < 0.01). While the 5-year distant metastasis rate (36.8% vs. 43.6%) was not statistically significant (P > 0.05).
Comparison of adverse reactions
Two patients in control group and four patients in hyperthermia group presented skin moist dermatitis on the neck when the radiation dose was 45 to 55 Gy. After short suspension of radiotherapy and corresponding treatment for skin moist dermatitis, the skin healed and the treatment for NPC was continued. The moist dermatitis incidence was 5.7% (4/76) in hyperthermia group, and 2.6% in control group (2/78). The skin reaction was severe in hyperthermia group but without statistically significant difference (P > 0.05). No severe sequela or complication was observed in all patients during the five years followup. Data are not shown.
In hyperthermia group, 15 patients died of distant metastasis, including 3 cases of widespread metastases, 4 cases of liver metastases, 5 cases of lung metastases, and 3 cases of bone metastases. In control group, 17 patients died of distant metastasis, including 4 cases of widespread metastases, 5 cases of liver metastases, 4 cases of lung metastases, and 4 cases of bone metastases. In hyperthermia group, 6 patients died of recurrent NPC and nasopharyngeal bleeding, without cervical lymph node recurrence. While in control group, 6 patients died of recurrent NPC, 10 cases died of cervical and nasopharynx lymph node recurrence, including 3 cases of nasopharyngeal bleeding. Eight patients remained relapsed after second radiation. Data are not shown.
Hyperthermia pattern dose not affect regression of cervical lymph nodes
In order to evaluate the effect of hyperthermia pattern on regression of cervical lymph nodes, 76 patients in hyperthermia group were treated differently, with 36 patients received hyperthermia before radiotherapy and 40 patients received hyperthermia after radiotherapy. There was no significant difference in gender, age, KPS score, histological type, clinical stage and N stage between these of patients with different hyperthermia pattern (P > 0.05). The regression of cervical lymph nodes at 3 months and 5 years after treatment were evaluated, as shown in Table 3 . The differences between hyperthermia before radiotherapy treatment and hyperthermia after radiotherapy treatment in CR rate were not significant (77.8% vs. 82.5%, 91.7% vs. 95.0%) (P > 0.05).
Heating temperature of T90 ≥ 43°C has higher cervical lymph node regression rate
Seventy cases of patients from hyperthermia group with well temperature curve were further analyzed for heat dosage. They were divided into patients with T90 < 43°C treatment (28 cases) and patients with T90 ≥ 43°C treatment (42 cases). There was no significant difference in gender, age, KPS score, histological type, clinical stage and N stage between these patients with different heating temperature (P > 0.05). At 3 months after treatment, the CR rate in patients with T90 < 43°C treatment and T90 ≥ 43°C treatment were 64.3% and 85.7% while the PR rate were 35.7% and 14.3%, respectively. And at 5 years after treatment, the CR rate in patients with T90 < 43°C treatment and T90 ≥ 43°C treatment were 85.7% and 97.6%, respectively. Statistically, the differences between T90 < 43°C treatment and T90 ≥ 43°C treatment were significant (P < 0.05). Therefore, the efficacy of cervical DOI:http://dx.doi.org/10.7314/APJCP.2013.14.12.7395 Microwave Hyperthermia for Control of Nasopharyngeal Cancer lymph node regression in patients with T90 ≥ 43°C treatment was significantly higher than that in patients with T90 < 43°C treatment, as shown in Table 4 .
Hyperthermia treatment times of 4-10 times have higher cervical lymph node regression rate
Patients in hyperthermia group received different amount of hyperthermia and the efficacy of different times of hyperthermia was compared at 3 months and 5 years after treatment (Table 5 ). There was no significant difference in gender, age, KPS score, histological type, clinical stage and N stage among these patients (P > 0.05). The CR rate was highest when the hyperthermia was 4-10 times at 3 months and 5 years after treatment (81.6% and 97.4%). Meanwhile, the PR rate was the lowest when the hyperthermia was 4-10 times (18.4% and 2.6%). And compared with patients with hyperthermia times of < 4 times and > 10 times, patients with hyperthermia times of 4-10 times had significantly higher regression rate (P < 0.05).
Discussion
In this study, complete lymph node regression rate in hyperthermia group and control group was 81.6% and 62.8% at 3 months after treatment (P < 0.05), and local control rate of cervical lymph node was significantly higher in hyperthermia group than that in control group at 5 years after treatment (P < 0.01). The 3-year and 5-year survival rate was statistically significant (P < 0.05). The 5-year DFS rate was statistically significant (P < 0.01).
The 5-year distant metastasis rate was 36.8% and 43.6% respectively in hyperthermia group and control group, without significant difference (P > 0.05). Our results showed that local control rate of cervical lymph nodes, 3-year and 5-year survival rate and 5-year DFS rate was significantly higher in hyperthermia group, indicating that local hyperthermia can increase local control rate of cervical lymph nodes. In this study, there was no significant difference in the efficacy of distant metastasis control between the two groups. This might be associated with inadequate number of cases, or with the status of nasopharyngeal lesions, which needs to be further improved. Moreover, we observed some late toxicities (data not shown). The most common late toxicities were of grades 1 and 2 among patients with 5 years of follow-up. The skin reaction was severe in hyperthermia group but without statistically significant difference (P > 0.05). No severe sequela, or complication was observed in all patients during the five years follow-up. There was no significant difference of adverse reactions between the hyperthermia group and the control group. Deng et al. (2002) found that hyperthermia combined with radiotherapy and chemotherapy treatment could significantly improve the local control rate for patients with NPC staging in III and IVa without increasing toxicity, which was in accordance with this study.
Although hyperthermia with radiotherapy has been used for many years, the implement of hyperthermia such as its timing, treatment times and temperature is still controversial. Liu et al. (2005) showed that there was no significant difference in different procedure (hyperthermia before radiotherapy or radiotherapy after hyperthermia) on the inhibition rate of HeLa cells (P > 0.05). With same procedure but different time intervals (30 min, 2 h, 24 h), there was also no significant difference of inhibition rate on HeLa cells (P > 0.05). In this study, the cervical lymph nodes regression rate in patients with hyperthermia before radiotherapy treatment and those with hyperthermia after radiotherapy treatment was not statistically significant (P > 0.05). This data suggest that there was no significant difference in lymph node metastasis regression between hyperthermia before radiotherapy treatment and hyperthermia after radiotherapy treatment. And this data was consistent with findings of He et al. (2002) in esophageal cancer.
For the comprehensive treatment of superficial tumor with hyperthermia and radiotherapy, different hyperthermia times (such as 3-14 times) had different efficacies (Li and Hu, 1995; Liu et al., 1997) . It is indicated that the number of hyperthermia is associated with clinical efficacy. In this study, we showed that CR rate were 66.7% (3-month CR rate) and 73.3% (5-year CR rate) in patients treated with hyperthermia < 4 times, 81.6% (3-month CR rate) and 97.4% (5-year CR rate) in patients treated with hyperthermia 4 -10 times, and 69.6% (3-month CR rate) and 82.6% (5-year CR rate) in patients with hyperthermia > 10 times. Thus this result indicates that less than 4 times or more than 10 times of hyperthermia could not increase CR rate in tumor of relatively larger volume. Increasing the number of hyperthermia will not only increase the financial burden on patients, but also increase the incidence of heat injury.
It is reported that cell damage from temperature below 43°C is different from that over 43°C. The cytotoxicity target is different with temperature above 43°C and below 42.5°C. Thermal resistance can be changed in the heating process with temperature below 43°C. However, when temperature is above 43°C, thermal resistance cannot be further developed. Kapp and Cox (Kapp and Cox, 1995) analyzed the efficacy of 332 times of hyperthermia combined with radiotherapy in 83 cases of recurrent or metastatic breast cancer patients using the "heat map" or multi-point temperature measurement technology. They found that cumulative Eq min T90 at 43°C was significantly related with CR rate (P < 0.01) and with local control rate (P < 0.01). In this study, we showed that at 3 months after treatment, regression rate of cervical lymph node was 85.7% and 64.3% in patients with T90 ≥ 43°C treatment and those with T90 < 43°C treatment, and 97.6% and 85.7% at 5 years after treatment. The difference between patients with T90 ≥ 43°C treatment and those with T90 < 43°C treatment was statistically significant (P < 0.05).
In conclusion, microwave hyperthermia is easy to implement without significant side effects. For example, radiation skin reactions will not be increased by hyperthermia with carefully operating. Therefore, combination of hyperthermia with radiotherapy and chemotherapy for the treatment of cervical lymph node metastasis of NPC is an effective therapy that worth further study.
